期刊文献+

咪唑立宾治疗儿童激素依赖性肾病综合征的疗效观察 被引量:7

下载PDF
导出
摘要 目的观察分析咪唑立宾治疗儿童激素依赖性肾病综合征的临床疗效。方法 10例激素依赖性肾病综合征患儿入院后口服咪唑立宾,剂量为5 mg/(kg.d),疗程3个月,同时联合标准激素治疗1.5 mg/(kg.d)。治疗前及治疗后8、12周观察24 h尿蛋白定量、血浆白蛋白、血浆胆固醇、血肌酐、尿素氮等指标。10例中8例行肾活检,了解病理类型。结果 10例患儿经治疗后,完全缓解6例(60%),部分缓解2例(20%),未缓解2例(20%)。患儿治疗后各项生化指标均较治疗前明显好转,治疗前后结果差异有统计学意义(P<0.05)。8例肾活检病理为微小病变型2例,系膜增生性肾炎4例,局灶节段性肾小球硬化2例。结论咪唑立宾联合激素能有效治疗儿童激素依赖性肾病综合征,值得临床应用。
出处 《广东医学》 CAS CSCD 北大核心 2013年第16期2573-2574,共2页 Guangdong Medical Journal
  • 相关文献

参考文献11

  • 1儿童常见肾脏疾病诊治循证指南(一):激素敏感、复发/依赖肾病综合征诊治循证指南(试行)[J].中华儿科杂志,2009,47(3):167-170. 被引量:350
  • 2KUSUMI T, TSUDA M, KATSUNUMA T, et al. Dual inhibitory effect of mizoribine[J]. Cell Biochem Funct, 1989, 7(3) : 201 -204.
  • 3谢院生.咪唑立宾在肾脏病中的应用[J].中国中西医结合肾病杂志,2008,9(7):565-568. 被引量:6
  • 4YOKOTA S. Mizoribine : mode of action and effects in clinical use [J]. Pediatr Int, 2002, 44(2): 196-198.
  • 5KAWASAKI Y, SUZUKI J, SAKAI N, et al. Efficacy of Prednis- olone and mizoribine therapy for diffuse IgA nephropathy[ J]. Am J Nephrol, 2004, 24(1) : 147 -153.
  • 6YUMURA W, SUGANUMA S, UEHIDA K, et al. Effects of long - term treatment with Mizoribine in patients with proliferative lupus nephritis[ J]. Clin Nephrol, 2005, 64( 1 ) : 28 - 34.
  • 7SHIBASAKI T, KOYAMA A, HJSHIDA A, et al. A randomized open -label comparative study of eonventional therapy versus mi- zoribine onlay therapy in Patients with steroid - resistant nephrotic syndrome (postmarketing survey) [ J]. Clin Exp Nephrol, 2004, 8(2): 117 - 126.
  • 8KAWASAKI Y, HOSOYA M, KOBAYASHI S, et al. Oral mizor- ibine pulse therapy for patients with steroid - resistant and fre- quently rdapsing steroid - dependent nephrotic syndrome [ J ]. Nephrol Dial Transplant, 2005, 20(10) : 2243 -2246.
  • 9HONDA M. Nephrotic syndrome and mizoribine in children [ J ]. Pediatr Int, 2002, 44(2): 210-216.
  • 10NISHI E, KAMEDA H, OGAWA H, et al. Efficacy of weekly mi- zoribine pulse therapy in refractory lupus nephritis [ J ]. Mod Rheu- matol, 2012, 23(1): 97-103.

二级参考文献64

  • 1孙嫱,沈颖.Meta分析评价环磷酰胺对儿童肾病综合征的治疗作用[J].中华儿科杂志,2006,44(3):199-201. 被引量:20
  • 2钱叶勇,石炳毅,敖建华,肖序仁,马潞林,田野,杜林栋.咪唑立宾在肾移植术后的应用[J].中华器官移植杂志,2006,27(12):723-724. 被引量:13
  • 3莫樱,陈述枚.肾病综合征频复发及激素依赖的治疗[J].中国实用儿科杂志,2007,22(6):412-416. 被引量:12
  • 4刘书馨,谢院生,陈香美,吕杨,傅博,尹忠,洪权.咪唑立宾对大鼠肾小球系膜细胞增殖的抑制作用[J].中华肾脏病杂志,2007,23(7):438-441. 被引量:9
  • 5Filler G, Young E, Geier P, et al. Is there really an increase in non-minimal change nephrotic syndrome in children? Am J Kidney Dis ,2003,42 : 1107-1113.
  • 6Eddy AA,Symons JM. Nephrotic syndrome in childhood. Lancet, 2003.362:629-639.
  • 7Wong W. Idiopathic nephrotic syndrome in New Zealand children, demographic, clinical features, initial management and outcome after twelve-month follow-up: results of a three-year national surveillance study. J Pedia Child Health,2007,43:337-341.
  • 8易著文.小儿临床肾脏病学//易著文,钟巧.肾病综合征.北京:人民卫生出版社,1998:346-361.
  • 9Koskinies O, Vilska J, Rapola J, et al. Long-term outcome of primary nephrotic syndrome. Arch Dis Child, 1987,57:544-548.
  • 10Tarshish P, Tobin JN, Bwenstein J,et al. Prognostic significance of the early course of minimal change nephrotic syndrome:report of the International Study of Kidney Disease in Children. J Am Soc Nephrol, 1997,8:769-779.

共引文献354

同被引文献74

  • 1中华医学会儿科学分会肾脏病学组.2004年全国儿童血尿暨慢性肾衰竭专题讨论会纪要[J].中华儿科杂志,2005,43(2):105-107. 被引量:14
  • 2孙嫱,沈颖.Meta分析评价环磷酰胺对儿童肾病综合征的治疗作用[J].中华儿科杂志,2006,44(3):199-201. 被引量:20
  • 3焦正,杨洁,张明,施孝金.高效液相色谱法测定人血浆中咪唑立宾的浓度[J].中国新药与临床杂志,2006,25(7):489-491. 被引量:10
  • 4莫樱,陈述枚.肾病综合征频复发及激素依赖的治疗[J].中国实用儿科杂志,2007,22(6):412-416. 被引量:12
  • 5Lombel RM, Hodson EM, Gipson DS, et al. Kidney disease : im- proving global outcomes.Treatment of steroid-resistant nephrot- ic syndrome in children:new guidelines from KDIGO [J]. Pedi- atr Nephrol, 2013,28 : 409-414.
  • 6Yokota S. Mizoribine: mode of action and effects in clinical use[J]. Pediatr Int,2002,44:196-198.
  • 7Takahara S, Takahashi K, Akiyama T, et al. Randomized com- parative trial of mizoribine versus mycophenolate mofetil in com- bination with tacrolimus for living donor renal transplanta- tion [ ] ]. Clin Exp Nephro|, 2013,17 (6) : 899-904.
  • 8Stypinski D, Obaidi M, Combs M, et al. Safety, tolerability and pharmacokinetics of higher-dose mizoribine in healthy male vol- unteers [ J ]. Br J Clin Pharmacol, 2007,63 (4) : 459-468.
  • 9Fuke T, Abe Y, Hibino S, et al. Mizoribine requires individual dosing due to variation of bioavailability [J]. Pediatr Int, 2012, 54(6) : 885-891.
  • 10Picard-Jean F, Bougie , Shuto S, et al. The immunosuppressive agent mizoribine monophosphate is an inhibitor of the human RNA capping enzyme[J]. PLOS ONE,2013,8( 1 ) :54621.

引证文献7

二级引证文献346

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部